Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Nader Damfu"'
Autor:
Hassan Almarhabi, Aisha Alharbi, Mai Alalawi, Mohamed Firoze Ahamed, Ihab El-Hemaidi, Nader Damfu
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 10, Pp 102526- (2024)
Patients with hematological malignancies are at increased risk of persistent coronavirus disease 2019 (COVID-19) infection, a unique clinical condition, for which the optimal treatment is unknown. Here we report a case of persistent COVID-19 in acute
Externí odkaz:
https://doaj.org/article/ad715c7cd5794969861095fb9fdf30c2
Autor:
Yazed Saleh Alsowaida, Khalid Al Sulaiman, Ahmad J. Mahrous, Aisha Alharbi, Nisrin Bifari, Walaa A. Alshahrani, Thamer A. Almangour, Nader Damfu, Aseel A. Banamah, Raghad R. Abu Raya, Raghad A. Sadawi, Arwa Alharbi, Ahmed Alsolami, Yahya Essa, Alaa Ghaze Almagthali, Shahad F. Alhejaili, Wed A. Qawwas, Ghaida Salamah Alharbi, Atheer Suleiman Alkeraidees, Afnan Alshomrani, Manal A. Aljohani, Ohoud Aljuhani
Publikováno v:
International Journal of Infectious Diseases, Vol 148, Iss , Pp 107234- (2024)
Objectives: To evaluate the clinical outcomes of anidulafungin for candidemia treatment in critically ill patients with obesity. Methods: A multicenter, retrospective cohort study was conducted in Saudi Arabia for critically ill adults with candidemi
Externí odkaz:
https://doaj.org/article/61c42b3ea68d496ba16783183ab94eba
Autor:
Namareq Fahad Aldardeer, Ismael Qushmaq, Bashayer Mohammed AlShehail, Nadia H. Ismail, Bayader S. Kalkatawi, Abrar Fahad AlHameed, Nader Damfu, Bashaer Y. Saber, Renad Nadhreen, Aiman M. Elsaed Ramdan, Mohammed Aldhaeefi, Mohammad Al Musawa, Abrar K. Thabit, Mohannad E. Nasser, Abeer Nizar Al Shukairi
Publikováno v:
Journal of Infection and Public Health, Vol 17, Iss 6, Pp 1147- (2024)
Externí odkaz:
https://doaj.org/article/93fdfb8a4c9946f0b4c47ebd37745b9f
Autor:
Yahya Ali Mohzari, Mohammed AL Musawa, Ahmad Alrashed, Bandar Zaeri, Nader Damfu, Peter Cahusac, Sana Alwafai, Ahmad Alamer, Abdulaziz Almulhim
Publikováno v:
Journal of Infection and Public Health, Vol 16, Iss 12, Pp 2026-2030 (2023)
Background: People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfectio
Externí odkaz:
https://doaj.org/article/528e2040b47e4934be6c897f67919a7f
Autor:
Namareq Aldardeer, Ismael Qushmaq, Bashayer AlShehail, Nadia Ismail, Abrar AlHameed, Nader Damfu, Mohammad Al Musawa, Renad Nadhreen, Bayader Kalkatawi, Bashaer Saber, Mohannad Nasser, Aiman Ramdan, Abrar Thabit, Mohammed Aldhaeefi, Abeer Al Shukairi
Publikováno v:
Journal of Epidemiology and Global Health, Vol 13, Iss 3, Pp 444-452 (2023)
Abstract Purpose Antibiotic de-escalation (ADE) in critically ill patients is controversial. Previous studies mainly focused on mortality; however, data are lacking about superinfection. Therefore, we aimed to identify the impact of ADE versus contin
Externí odkaz:
https://doaj.org/article/4f0266b4a9644bf7824e6faedec4b345
Autor:
Abrar F. Alhameed, Nada Saferuddin, Tariq Alturkistani, Mohammed Al Musawa, Nader Damfu, Majda Alattas
Publikováno v:
Heliyon, Vol 9, Iss 11, Pp e22053- (2023)
Background: The 2017 Infectious Diseases Society of America (IDSA) Clostridioides difficile infection (CDI) guidelines recommendation for oral vancomycin as preferred treatment was based on studies conducted in North America, Australia, and Europe. A
Externí odkaz:
https://doaj.org/article/f819404553ce449486baa4be1bbb9ce9
Autor:
Thamer A. Almangour, Ahmad Aljabri, Mohammed Al Musawa, Abdullah Almohaizeie, Sara Almuhisen, Nader Damfu, Awaly Alfozan, Basem M. Alraddadi, Majda Alattas, Mohammed Qutub, Abrar F. Alhameed, Malik Khuwaja, Ahlam Alghamdi, Khalifa M. Binkhamis, Wafa Alfahad, Fatimah S. AlShahrani
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 28, Iss , Pp 288-294 (2022)
ABSTRACT: Objectives: The aim of this study was to compare the safety and effectiveness of ceftolozane-tazobactam (C-T) to colistin-based regimen for treating infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Methods: This was a
Externí odkaz:
https://doaj.org/article/8cc7bf460bc04587a8c8c945a2b28dbe
Autor:
Shaimaa Alsulami PharmD, BCPPS, Sultan N. Alotaibi PharmD, BCPS, BCIDP, Nader Damfu PharmD, BCPS, BCIDP, Doaa M. Aljefri PharmD, MSc, BCIDP, Hadeel Ahmed Altayib MD, Maher Alharbi MD
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 21 (2022)
Bictegravir (BIC) is included in international guidelines as the first line of therapy for patients living with Human Immunodeficiency Virus (HIV), either as initial therapy or as a replacement for patients with prior antiretroviral therapy (ART). Du
Externí odkaz:
https://doaj.org/article/1cc9e3b58a9f43ee958d8b0f65891fa0
Autor:
Thamer A Almangour, Leen Ghonem, Ahmad Aljabri, Alya Alruwaili, Mohammed Al Musawa, Nader Damfu, Mesfer S Almalki, Majda Alattas, Hossam Abed, Doaa Naeem, Nawaf Almalki, Abdullah A Alhifany
Publikováno v:
Infection and Drug Resistance
Thamer A Almangour,1 Leen Ghonem,2 Ahmad Aljabri,2 Alya Alruwaili,3 Mohammed Al Musawa,4 Nader Damfu,5 Mesfer S Almalki,6 Majda Alattas,4 Hossam Abed,4 Doaa Naeem,5 Nawaf Almalki,5 Abdullah A Alhifany7 1Department of Clinical Pharmacy, College of Pha
Publikováno v:
Open Forum Infectious Diseases. 9
Background Limited data are available for Ceftazidime-avibactam (CAZ AVI) dosing in patients with chronic kidney diseases. High rate of treatment failure was found among patients with chronic kidney diseases for which renally adjusted doses has been